45 results about "Anti-inflammatory response" patented technology

A barrier layer and corresponding method of making provide anti-inflammatory, non-inflammatory, and anti-adhesion functionality for a medical device implantable in a patient. The barrier layer can be combined with a medical device structure to provide anti-adhesion characteristics, in addition to improved healing, non-inflammatory, and anti-inflammatory response. The barrier layer is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent.

A barrier layer and corresponding method of making provide anti-inflammatory and anti-adhesion functionality for a medical device implantable in a patient. The barrier layer can be combined with a medical device structure to provide anti-adhesion characteristics, in addition to improved healing and anti-inflammatory response. The barrier layer is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel derived from at least one fatty acid compound. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent.

A method of UV curing and corresponding resulting non-polymeric cross-linked gel are provided. The cross-linked gel can be combined with a medical device structure. The cross-linked gel can provide anti-adhesion characteristics, in addition to improved healing and anti-inflammatory response. The cross-linked gel is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel derived from at least one fatty acid compound. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent. The curing method can vary the application of UV light in both intensity and duration to achieve a desired amount of cross-linking forming the gel.

The present invention provides, among other things, improved compositions and methods for the treatment of tissue damage (e.g., acute or chronic) and related diseases, disorders or conditions based on the use of pathfinder cells, extracellular secretomes thereof, and / or pathfinder cell-associated microRNAs. In some embodiments, the present invention provides a method for treating tissue damage (e.g., acute or chronic) comprising a step of administering a population of cells to an individual suffering from a disease, disorder or condition characterized by acute damage to one or more tissues, wherein the cells are originated from an adult tissue and wherein the cells induce tissue repair, regeneration, remodeling, reconstitution or differentiation. In some embodiments, the present invention provides a method for treating inflammation comprising a step of administering a population of cells, or extracellular secretomes thereof, to an individual suffering from a disease, disorder or condition characterized by inflammation of one or more tissues, wherein the cells are originated from an adult tissue and wherein the cells induce an anti-inflammatory response.

The invention relates to a prenylated flavonoid, and applications thereof in preparing drugs used for treating inflammatory diseases. The prenylated flavonoid is a novel compound separated from artocarpus heterophyllus of Artocarpus, Moraceae, and is named as artoheteroid C. The structure of artoheteroid C is disclosed in the invention, possesses high inhibition activity on mouse neutrophil respiratory burst, can be used for preparing drugs used for treating inflammatory diseases, and can be used for clinical treatment of oxidative damages, such as rheumatoid arthritis, compensatory anti-inflammatory response syndrome, and systemic inflammatory response syndrome, caused by neutrophil excessive activation; and the IC50 value is 7.5<mu>M.

The present invention provides methods for stimulating Toll-like receptors (TLR) to activate IRF (e.g., an IRF3) and signaling pathway, and thereby directing an antimicrobial activity. The present invention also provides methods for identifying agents that bind and / or stimulate TLR and mediate induction of an IRF3 pathway, thereby directing an antimicrobial activity. Additionally, the invention provides methods and agents for suppressing stimulation of TLR, thereby directing an anti-inflammatory response.

Disclosed are compositions, including LcrV antigenic polypeptides, vaccines and antibodies, as well as associated methods for treating and / or preventing Yersinia infection in a host. The invention further provides immunomodulatory LcrV proteins and polypeptides comprising TLR2 and IFN-gammaR-IFN-gamma-binding sequences that stimulate host anti-inflammatory responses and repress pro-inflammatory responses.

The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.

Described herein are anti-inflammatory fractions and compounds, medicaments, methods and uses thereof. The fraction may be obtained from honey. The fraction shows a generalised anti-inflammatory response. Also described are method f producing the fraction as well as a method of testing the anti-inflammatory potential of a honey by completing the fractionation and a cell test.

The present disclosure provides methods for obtaining gaultherin, a natural salicylate derivative, from plant tissue. The methods involve preventing the hydrolysis of the gaultherin in the plant tissue by disrupting the plant tissue under solvent conditions lacking a drying agent. The disclosure further provides various forms of plant-derived gaultherin, including alcoholic extracts, aqueous solutions and dried preparations, all suitable for use as a natural aspirin substitute. Moreover, the disclosure provides methods of using gaultherin-containing compositions to increase serum salicylic acid, to treat cancer cells, to treat cardiovascular (e.g., cardiopulmonary) conditions, to treat anti-inflammatory responses, and to inhibit cyclooxygenase.

A method of upregulating an anti-inflammatory response in a central nervous system (CNS) of a subject in need thereof is disclosed. The method comprising locally administering to the CNS of the subject a therapeutically effective amount of IFN-beta, thereby upregulating the anti-inflammatory response in the CNS of the subject. Methods of treating an inflammation in a CNS or treating a disease, disorder, condition or injury of a CNS of a subject are also disclosed.

The invention relates to a drug for promoting recovery from chronic spinal cord injury and a preparation method and application thereof. The technical problem to be solved by the invention is to provide a new option for the treatment of spinal cord injury. The technical scheme of the invention is a drug for promoting recovery from spinal cord injury, and a main active ingredient of the drug is a specific histone deacetylase 3 inhibitor RGFP966. The invention discloses a novel function of RGFP966 treatment by inhibiting HDAC to inhibit inflammatory reaction, promote anti-inflammatory reaction,promote axon regeneration and promote functional recovery after chronic spinal cord injury, thereby indicating a new direction for immunoregulation of spinal cord injury repairing.

The invention discloses phosphatidylserine-modified curcumin nanoparticles; with biological endogenous phosphatidylserine (PS) as a membrane material, an anti-inflammatory drug curcumin is coated, and the PS-modified curcumin nanoparticle targeted drug delivery system is prepared; through simulating apoptotic cells, curcumin nanoparticles are identified by specific receptors on the surface of macrophages, and in virtue of the receptor mediated macrophage active targeting effect, macrophage uptake is enhanced; the drug curcumin enters the macrophages, then the anti-inflammatory effect is exerted, at the same time, a PS carrier is taken in, then the macrophages are induced to produce anti-inflammatory response, that is to say, release of pro-inflammatory cytokines is reduced, secretion of anti-inflammatory cytokines is increased, and the drug and carrier synergistic anti-inflammatory effect is reached; the PS-modified curcumin nanoparticles can be used for application of drugs for treating macrophage mediated related diseases.

The present invention provides compositions having synergistic antioxidant properties in the modulation of Toll-like receptor signaling for the promotion of homeostasis, immunity, energy conservation, protection of neural cells and anti-inflammatory responses, said compositions comprising plant and / or fruit extracts and a natural sweetener with high oxidation potential as defined by ORAC value.

The present invention relates to a composition for reducing skin wrinkles or inflammation, containing a substance P (SP)-containing composition as an active ingredient and, more specifically, to: a novel use of a composition containing SP for reducing skin wrinkles or inflammation by promoting collagen synthesis, inhibiting collagenase generation, and performing an anti-inflammatory reaction; anda cosmetic composition for reducing skin wrinkles and inflammation, containing the composition. The SP-containing composition of the present invention exhibited an improved skin wrinkle or inflammation reduction effect over that of SP by means of the synergistic action achieved by an antioxidant, a surfactant, and a thickening agent which are added for stabilizing SP with respect to the basic characteristics of SP, which is conventionally known to be effective for reducing skin wrinkles or inflammation. Therefore, the composition of the present invention can be useful as a cosmetic compositionfor reducing skin wrinkles or inflammation.

The invention relates to a novel compound of a structure formula (I). The compound can be extracted and separated from a dried whole plant of Erigeron breviscapus (Vant.) Hand.-Mazz. The compound has anti-inflammatory response, anti-platelet aggregation, anti-thrombotic and vasodilator effects, and can be used for preparing a medicament for treating cardiovascular and cerebrovascular diseases. The structure formula (I) is shown below.

The invention relates to isopentenyl stilbene and application thereof to preparation of drugs for treating inflammatory diseases. The isopentenyl stilbene is a new compound separated from artocarpus styracifolius Pierre which is a moraceae artocarpus plant, is named (+ / -)-artocarpus styracifolius phenol D, and has a structure as shown in the following description. The compound has strong inhibitory activity on rat polymorphonuclear neutrophils (PMNs) respiratory burst, the IC50 is 1.5+ / -0.22 muM, and the compound can be further used for preparing the drugs for treating the inflammatory diseases, and is used in clinical treatment of various oxidative damage, such as rheumatoid arthritis, compensatory anti-inflammatory response syndrome (CARS), and systemic inflammatory response syndrome (SIRS), caused by the excessive activation of PMNs.

Compositions and methods relating to WSX-1 and p28 (IL-30) are provided. In particular, methods of treating inflammatory conditions in mammalian subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and complexes or moieties that bind to or modulate activity of such complexes are described. Isolated or recombinant complexes including soluble WSX-1 or gp130 polypeptides, isolated or recombinant WSX-1 fusion proteins, and isolated or recombinant p28 fusion proteins are also described.

The invention discloses an anti-atherosclerosis drug efficacy evaluation method based on inflammatory responses, wherein the method comprises the following steps: step 1, planting smooth muscle cells on the outer side of a Millicell@insert PE (Poly Ethylene) membrane, and turning after the cells are adhered to the wall for 8 hours; step 2, planting endothelial cells on the inner side of the membrane, and culturing for 6 days totally; step 3, inoculating mononuclear cells THP-1, adding oxLDL, IL-1 and texted drugs, and culturing for 24 hours; step 4, detecting any one of the items of detecting contents of MCP-1 and TNFa in the endothelial cells; detecting the content of CD36 on the surface of the mononuclear cells; detecting the contents of MDA and MMP2 in the smooth muscle cells, observing the change of a smooth muscle cytoskeleton; observing the expression of ICAM-1 of the endothelial cells.

Described herein are anti-inflammatory fractions and compounds, medicaments, methods and uses thereof. The fraction may be obtained from honey. The fraction shows a generalised anti-inflammatory response. Also described are method f producing the fraction as well as a method of testing the anti-inflammatory potential of a honey by completing the fractionation and a cell test.

The invention relates to a stilbene derivative and application thereof to preparation of drugs for treating inflammatory diseases. The stilbene derivative is a new compound separated from artocarpus styracifolius Pierre which is a moraceae artocarpus plant, is named (+ / -)-artocarpus styracifolius phenol C, and has a structure as shown in the following description. The compound has strong inhibitory activity on rat polymorphonuclear neutrophils (PMNs) respiratory burst, the IC50 is 4.24+ / -0.58 muM, and the compound can be further used for preparing the drugs for treating the inflammatory diseases, and is used in clinical treatment of various oxidative damage, such as rheumatoid arthritis, compensatory anti-inflammatory response syndrome (CARS) and systemic inflammatory response syndrome (SIRS), caused by the excessive activation of PMNs.

Heme released as a result of sustained injury leads to toxicity and triggers an inflammatory response and tissue damage. Heme oxygenase, an enzyme, recognizes, binds free heme and breaks it down as a part of the anti-inflammatory response. The present disclosure relates to a class of peptide amphiphiles that mimic the heme oxygenase function, and have shown that the designed peptide is able to bind and break down heme thus validating its potential as an anti-inflammatory agent that promotes tissue repair and useful in wound healing. The disclosed peptide sequence design provides control of amphiphile peptides' supramolecular structure and function. Applicants have shown that the incorporated heme molecule can transport CO, which suggests that the peptides can also transport NO, O2 and reactive oxygens, the molecules which are responsible for vasodilation, neurotransmission and cell death. Besides heme oxygenase function, it is believed that the designed peptides can recognize normal tissue adjacent to the damaged area and the peptide can self-assemble into fibers that promote healthy cell growth.